{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:52:14Z","timestamp":1780084334970,"version":"3.54.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,17]]},"DOI":"10.7759\/cureus.29264","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T17:37:38Z","timestamp":1663436258000},"source":"Crossref","is-referenced-by-count":5,"title":["A Rare but Life-Threatening Case of Fournier\u2019s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin"],"prefix":"10.7759","author":[{"given":"Tahmina","family":"Jahir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobasera","family":"Bagum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Saidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Risal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Necrotizing soft tissue infections\r\n. (2022). Accessed. April 03, 2022: https:\/\/www.uptodate.com\/contents\/necrotizing-soft-tissue-infections."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo RA","year":"2021","unstructured":"DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021, 17:319-34. 10.1038\/s41581-021-00393-8","journal-title":"Nat Rev Nephrol"},{"key":"ref3","article-title":"Sodium-glucose co-transporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus","author":"DeSantis A","year":"2022","unstructured":"DeSantis A. Sodium-glucose co-transporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus. Nathan DM, Rubinow K (ed): UpToDate, Inc, 2022. 4:2022."},{"key":"ref4","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia DS","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017, 24:73-9.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref6","unstructured":"FDA Drug Safety Podcast. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. (2022). Accessed: April 03, 2022: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-drug-safety-podcast-fda-warns-about-rare-occurrences-serious-i...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00771-8","article-title":"SGLT2 Inhibitors and the risk of hospitalization for fournier's gangrene: a nested case-control study","volume":"11","author":"Wang T","year":"2020","unstructured":"Wang T, Patel SM, Hickman A, Liu X, Jones PL, Gantz I, Koro CE. SGLT2 Inhibitors and the risk of hospitalization for fournier's gangrene: a nested case-control study. Diabetes Ther. 2020, 11:711-23. 10.1007\/s13300-020-00771-8","journal-title":"Diabetes Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/cd21-0015","article-title":"Sodium-glucose cotransporter 2 inhibitor use associated with Fournier\u2019s gangrene: a review of case reports and spontaneous post-marketing cases","volume":"40","author":"Tran BA","year":"2022","unstructured":"Tran BA, Updike WH, Bullers K, Serag-Bolos E. Sodium-glucose cotransporter 2 inhibitor use associated with Fournier\u2019s gangrene: a review of case reports and spontaneous post-marketing cases. Clin Diabetes. 2022, 40:78-86. 10.2337\/cd21-0015","journal-title":"Clin Diabetes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3695101","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA adverse event reporting system","volume":"2020","author":"Hu Y","year":"2020","unstructured":"Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J, Mei D. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA adverse event reporting system. J Diabetes Res. 2020, 2020:3695101. 10.1155\/2020\/3695101","journal-title":"J Diabetes Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/102945-a-rare-but-life-threatening-case-of-fourniers-gangrene-caused-by-sodium-glucose-cotransporter-2-sglt2-inhibitor-empagliflozin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:30Z","timestamp":1707507570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/102945-a-rare-but-life-threatening-case-of-fourniers-gangrene-caused-by-sodium-glucose-cotransporter-2-sglt2-inhibitor-empagliflozin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.29264","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,17]]}}}